• AIM: To investigate the candidate microRNA (miRNA), miR-221 as a novel biomarker for diabetic retinopathy (DR) in patients associated with type 2 diabetes (T2D).
INTRODUCTION

W
ith the increasing global morbidity of diabetes, diabetic retinopathy (DR) is still the primary reason for incurable blindness of diabetic patients, which is featured as progressive microvascular complications owing to chronically hyperglycemia from diabetes [1] . About 1/3 have symptoms of DR in diabetic patients, moreover 1/3 of these maybe have visual impaired retinal pathology, realized as proliferative diabetic retinopathy (PDR) [2] . Furthermore, the manifestation of DR implies a dangerous factor of healththreatening systemic vascular complications [3] . Epidemiological and genetic researches have furthered our comprehension of the pathophysiology on DR [4] [5] [6] . Moreover, recent studies have unveiled an influential and unexpected role of epigenetics, notably microRNAs (miRNAs) in main biological processes, providing a unique perspective opportunity to translate this theoretical hypothesis into the clinical practice in the form of miRNA-based pathogenesis, diagnosis, treatment and prognosis for DR [7] [8] . miRNAs are short (about 22 nucleotides long) and highly conserved sequences of endogenous RNA that do not encode for any protein and represent a new powerful class of gene modulators [9] . They are expressed in all human cell-types and are involved in the main biological processes including cell growth, differentiation, and apoptosis [10] . Previous studies focusing on miR-221, suggested that the expression of miR-221 were significantly upregulated and may involve in the physiopathology of diabetes and macrovascular complications associated with type 2 diabetes (T2D) via specific target genes [11] [12] [13] . To validate the hypothesis based on previous studies, a cross-sectional study was conducted to identify whether serum miR-221 as a novel biomarker with high sensitivity and specificity for genetic diagnosis and biologic therapy in patients with DR according to the epigenetic methodology.
SUBJECTS AND METHODS
The current study was conformed to the contents of the Declaration of Helsinki, meanwhile was authorized by the Institutional Review Board/Ethics Committee of Shengjing Hospital, China Medical University. All subjects had written the informed consent before enrollment. Participants Participants were consecutively recruited from Shengjing Hospital, China Medical University between January 2015 and January 2016, afterwards divided to four study groups in accordance to Diabetic Retinopathy Disease Severity Scale based on fundus fluorescein angiography: healthy control (HC) group, HC participants; no diabetic retinopathy (NDR) group, T2D patients without DR; nonproliferative diabetic retinopathy (NPDR) group, T2D patients with NPDR; PDR group, T2D patients with PDR [14] . Exclusion criteria were other serious ocular and systemic diseases. Clinical history and medications were evaluated. All participants experienced ophthalmologic examination. Samples Collection Serum samples were collected and stored according to our previous study until further processing [15] . miRNA Quantification The expression level of serum miRNA was quantified by real-time quantitative reversetranscription polymerase chain reaction (qRT-PCR) according to our previous study [15] . Table 1 .
Relative Expression of Serum miR-221
There was a significantly difference in serum miR-221 level among four groups (P<0.001; Figure 1 ). The serum miR-221 in patients with T2D were significantly increased compared to HC group (P HC vs NDR =0.015, P HC vs NPDR <0.001, P HC vs PDR <0.001). Moreover, in patients with T2D, the serum miR-221 in NDR, NPDR and PDR groups were gradually increased, respectively (P NDR vs NPDR =0.025, P NDR vs PDR <0.001, P NPDR vs PDR =0.001).
Relative Expression of Serum Makers
There was a significant difference in serum Ang II level among the four groups, respectively (P<0.001; Figure 2 ). The serum Ang II in patients with T2D were significantly increased compared to HC group, respectively (P HC vs NDR <0.001, P HC vs NPDR <0.001, P HC vs PDR <0.001). Furthermore, in patients with T2D, the serum Ang II were stepwise increased in NDR, NPDR and PDR groups (P NDR vs NPDR <0.001, P NDR vs PDR <0.001, P NPDR vs PDR <0.001).
There was a significant difference in serum VEGF level among the four groups, respectively (P<0.001; Figure 2 ). The serum VEGF in patients with T2D were significantly increased compared to HC group, respectively (P HC vs NDR <0. Figure 4 ). DISCUSSION This cross-sectional study yielded almost consentaneous results that serum miR-221 was remarkably gradually increased with the severity of DR in T2D patients compared with HC subjects, and positive correlated with serum Ang II and VEGF in DR associated with T2D, moreover with a strong diagnostic efficiency for DR, give rise to identical recommendation with regard to miR-221 as a novel biomarker for on-set and development of DR associated with T2D. The pathogenesis of DR is a multifactorial affected by genetic and environmental factors [1] [2] . Hyperglycemia-related pathways have been proposed to initiate a cascade of interactions between physiological and pathological alterations, ultimately leading to retinal microvascular functional disorder, which was implied in the occurrence or progression of DR [1] [2] .
Epidemiological studies, clinical trials and experimental researches have indicated that previous experience in hyperglycemia has long-lasting outcomes, and DR continues to develop even after the euglycemia is initial, therefore implying a novel biomarker is necessary to identify individuals with high risk of progressive sight-threatening DR in patients with T2D [16] . Serum miRNA is apparently steady both in vivo and in vitro circumstance with multiple external conditions such as pH, temperature and pressure [17] . Generally, DR was characterized by microvascular structural and functional abnormalities, involving occlusion and leakage of retinal vessels, resulting in macular edema in the non-proliferative phase and angiogenesis and to tufts of highly permeable vessels in the proliferative phase. As a consequence, specific miRNAs could be selectively excessively secreted into the circulatory system through destroyed blood-retinal barrier via small membrane vesicles, such as exosomes, that are released into the extracellular environment [15] . Recently, there is growing evidence that the expression patterns and levels of specific miRNAs could reveal altered physiological and pathological conditions in both the microvascular and macrovascular complications of patients with T2D, and circulating miRNA is widely recognized to be as an attractive novel biomarker [18] . miR-221, that targets and binds to substantial genes and key factors of insulin/insulin-like signaling pathway, has been previously verified to be related to metabolic syndrome, diabetes and its complications [19] . Furthermore, under hyperglycemic conditions, significantly up-regulated miR-221 could induce cell proliferation, migration and apoptosis, lead to facilitate retinal vascular endothelial dysfunction, promote retinal vascular hyperplasia and occlusion to pursue retinal ischemia as well hypoxia, and expedite retinal neovascularization [20] . Consequently, aberrantly increased miR-221 can be detected in serum of patients with T2D, then gradually increased with the severity of DR could attributed to exacerbate blood-retinal barrier breakdown to aggravate casual retinal vascular damage and dysfunction exposed to hyperglycemic environment. Therefore, it has been implied that miR-221 may involve in angiogenesis, suggesting a new theory for DR in patients with T2D. The current quantitative results indicated that serum miR-221, Ang II and VEGF was significantly increased in T2D patients compared with HC subjects, and was regularly and markedly up-regulated in NDR, NPDR and PDR groups as well. The present qualitative results, ROC curves implied that miRNA-221, Ang II and VEGF with reasonable sensitivity and specificity have a promising diagnostic efficiency in DR respectively, among which miR-221 is the more noteworthy than others. The nowaday correlative results revealed that a significant positive correlation between miR-221 and metabolic parameters such as HbA1c and HOMA-IR, as well as serum markers for instance, Ang II and VEGF, respectively, suggesting miR-221 may involve in pathogenesis mechanism of DR in T2D patients.
Ang II, the main component in rennin-angiotensin system, which is considered as modulating retinal vascular architecture and function via role in vasoconstriction and angiogenesis has been implicated in DR [21] . VEGF, the pivotal angiogenic growth factor, which is thought to regulate retinal vascular structure as well as potence by effect on vasculogenesis and angiogenesis has been referred to DR [22] . Previous related studies could establish hypothesis that endothelial dysfunction associated with the development of DR is worsened by increased Ang II, which was induced by hyperglycemia, leading to activate JNK/c-Jun/mTOR signaling pathways, and thereby enhancing miR-221 expression through targeting cyclin-dependent kinase inhibitor 1B, furthermore, Ang II could potentiate the actions of VEGF-induced endothelial cell proliferation and migration via rennin-angiotensin system mediated mechanism, implying that Ang II may exacerbate or accentuate the expression and effect of VEGF via NADPH oxidase on retinal vascular endothelial cells [23] [24] [25] [26] . These implicated that miR-221 was highly associated with Ang II and VEGF resulting in the retinal vascular endothelial dysfunction under the hyperglycemia condition.
The current study has certain limitations. First of all, the study design is comparatively restricted, and the effect of investigative biomarkers in the progression of DR is still unknown due to lack of follow up. Second, the sample size is relatively limited, and the obtained results should be interpreted restrainedly and considered preliminary. Finally, the methodology is somewhat unilateral, and the observed correlation need to further validate via molecular mechanistic experiments.
The current cross-sectional study implies that miR-221 as a potential biomarker could be related to occurrence and progression of DR in patients with T2D. Nevertheless, a prospective, high-quality, large sample, long-term clinical trial coincided with experimental research is warranted to be further investigated.
